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Abstract: Osteoarthritis (OA) is the most prevalent arthritis worldwide and is characterized by 
chronic pain and impaired physical function. We hypothesized that heightened pain in hand OA 
could be reduced with duloxetine or pregabalin. In this prospective, randomized clinical study, 
we recruited 65 participants, aged 40–75 years, with a Numerical Rating Scale (NRS) for pain 
of at least 5. Participants were randomized to one of the following three groups: duloxetine, 
pregabalin, and placebo. The primary endpoint was the NRS pain score, and the secondary 
endpoints included the Australian and Canadian Hand Osteoarthritis Index (AUSCAN) pain, 
stiffness, and function scores and quantitative sensory testing by pain pressure algometry. After 
13 weeks, compared to placebo, ANOVA found significant differences between the three groups 
(P=0.0078). In the intention-to-treat analysis, the pregabalin group showed improvement for NRS 
pain (P=0.023), AUSCAN pain (P=0.008), and AUSCAN function (P=0.009), but no difference 
between duloxetine and placebo (P>0.05) was observed. In the per protocol analysis, NRS pain 
was reduced for pregabalin (P<0.0001) and duloxetine (P=0.029) compared to placebo. We 
conclude that centrally acting analgesics improve pain outcomes in people with hand arthritis, 
offering new treatment paradigms for OA pain.
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Introduction
Osteoarthritis (OA) is the most common form of arthritis worldwide, with hand pain 
and reduced function causing significant problems for people with hand OA.1 Pain is a 
major symptom for people with OA, with 16.7% of US adults aged 45 years and older 
reporting pain as a predominant problem.2 Pain and reduced function due to OA place a 
huge burden on patients and health care services.2,3 Although several pharmacological 
agents are available for OA pain management, including acetaminophen, nonsteroidal 
anti-inflammatory drugs (NSAIDs), and opioids, a large proportion of patients continue 
to suffer from chronic pain despite using the agents described.4,5 Recent trials have 
raised questions about current treatments, suggesting that acetaminophen has poor 
efficacy in controlling OA pain.6,7 Pain management in OA is a huge problem, and 
novel approaches are urgently needed.
Pain is often characterized as having features of inflammatory nociceptive pain and 
neuropathic components.8,9 OA is recognized to have features of inflammatory pain and 
also pain sensitization. Features of pain sensitization can be evaluated using quantita-
tive sensory testing (QST)10–13 and brain neuroimaging.14–16 Large studies have shown 
pain sensitization using QST in knee OA.10–13 Brain neuroimaging studies in chronic 
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OA have also demonstrated increased central pain processing 
in the cingulate cortex, insula, and thalamus compared with 
normal controls.14,15 Many clinical trials testing new agents 
for OA have focused on large joint hip and knee OA, but rela-
tively few trials have been conducted in hand OA. The ideal 
analgesic drug(s) in OA would achieve sustained pain relief 
in a dose-dependent manner with few side effects. Centrally 
acting analgesic drugs such as pregabalin and duloxetine could 
fulfill these criteria but have not been investigated in hand OA. 
Duloxetine is a serotonin and noradrenaline reuptake inhibitor 
(SNRI) that has shown efficacy for improving pain in knee 
OA.17 However, no previous studies have evaluated duloxetine 
in hand OA. Gabapentinoids are three-substituted derivatives 
of the neurotransmitter gamma-aminobutyric acid that blocks 
voltage-dependent calcium channels, used to treat epilepsy 
and neuropathic pain. Interest has grown in gabapentinoids 
for arthritis, since gabapentin inhibits pain sensitization.18,19 
Arthritic pain can be improved by NSAIDs and pregabalin 
in OA.20,21 Ohtori et al20 found that pregabalin combined with 
meloxicam was more effective for knee OA pain compared to 
either drug alone and Arendt-Nielsen et al21 showed that pain 
sensitization is improved by NSAIDs in knee OA.
We hypothesized that centrally acting analgesics may 
alleviate arthritic pain. We conducted a proof-of-concept, 
randomized, placebo-controlled study comparing duloxetine 
and pregabalin to placebo for hand OA pain. We used vali-
dated primary endpoints for pain, with secondary endpoints 
for pain sensitization using QST, depression, and anxiety 
scores. Our report is the first proof-of-concept clinical trial 
comparing the effect of centrally acting analgesics duloxetine 
and pregabalin head-to-head vs placebo in hand OA pain with 
mechanistic secondary endpoints for pain threshold testing.
Methods
Study design and participants
All methods were carried out in accordance with relevant 
guidelines and regulations. All trial protocols were approved 
by the sponsors, St George’s University of London and the 
Medicines and Healthcare Products Regulatory Agency, UK. 
Ethical approval was provided by the London-Surrey Borders 
Ethics Committee, approval number 12/LO/0047. Written 
informed consent was obtained from all subjects. The clini-
cal trial registration number is NCT02612233. Participants 
were eligible if they were aged 40–75 years and had hand 
OA diagnosed by American College of Rheumatology (ACR) 
criteria22,23 confirmed by a rheumatologist and experiencing 
pain of at least ≥5 on a Numerical Rating Scale (NRS) of 
0–10. The trial protocol was followed as published, according 
to CONSORT guidelines and inclusion–exclusion criteria. 
Twenty age-matched subjects without hand OA were enrolled 
as controls for comparisons for pain testing and brain MRI. 
The brain MRI data from this study will be reported in a 
separate publication.
Inclusion and exclusion criteria
Inclusion criteria were as follows: participants fulfilling the 
ACR criteria for the diagnosis of hand osteoarthritis, male or 
female, right or left handed, aged 40–75 years, and on usual 
care for hand OA including acetaminophen and/or NSAIDs. 
Exclusion criteria were another rheumatological diagnosis, 
eg, rheumatoid arthritis, current or planned pregnancy, con-
traindications to duloxetine or pregabalin such as concomitant 
use of monoamine oxidase inhibitors, selective serotonin 
reuptake inhibitors, antidepressants, oral contraceptives, St. 
John’s wort, history of depression, concomitant use of opioids 
including tramadol and pethidine, use of benzodiazepines, 
recent surgery, ie, <6 weeks prior to participation in the study, 
recent insertion of surgical implants, ie, <6 weeks before 
participation prior to entry, previous use of duloxetine and/
or pregabalin, uncontrolled depression, estimated glomerular 
filtration rate <60 mL/min, hepatic impairment defined as ALT 
>2.5× upper limit of normal within 6 weeks of last clinical 
assessment, ischemic heart disease, diabetes mellitus, and 
regular use of alcohol or alcohol abuse (maximum limits are 
28 units/week for men and 21 units/week for women, lactose 
intolerance). The estimated glomerular filtration rate was 
checked by screening blood tests, and any participants who 
were outside the stated range were not enrolled. Uncontrolled 
hypertension was checked by blood pressure in primary 
care, and any participants with a blood pressure >140/90 
were excluded. Baseline laboratory tests of renal function 
and hepatic function were performed at baseline to screen 
for any impairment, and participants with levels outside the 
normal range were excluded. We checked information from all 
participants about a new diagnosis of diabetes, and any new 
cases were excluded. For the Hospital Anxiety and Depres-
sion Scale (HADS) scoring, a score of ≥12 for anxiety and/
or depression was considered as too high for enrollment to 
the study and participants with a score of >12 were excluded.
Randomization and masking
Study drugs were supplied by Sharp Clinical Services (for-
merly Bilcare GCS, Powys, UK), which overencapsulated 
pregabalin 150 mg tablets or duloxetine 30 mg tablets and 
produced visually identical placebo capsules. A mid-ranging 
dose was selected for each of the trial medications. The 
random allocation sequence, with a block size of nine, was 
generated by the manufacturer and implemented through 
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sequentially numbered containers. Neither participants nor 
investigators were aware of treatment assignment until after 
completion of the trial, which was performed after the last 
patient and last visit were conducted at the end of the trial. 
Emergency code breaks were administered independently 
by the staff from the St George’s University Hospitals NHS 
Foundation Trust’s Clinical Trials Pharmacy.
Clinical outcome measures
The primary endpoints were the NRS and the Australian 
and Canadian Hand Osteoarthritis Index (AUSCAN) rating 
scale 3.1 for pain,24,25 which are validated outcome measures 
for pain. Both NRS and AUSCAN pain endpoints are well-
recognized primary endpoints in hand OA clinical trials and 
have been recommended in international guidelines.25,28
Prespecified secondary endpoints included the AUS-
CAN stiffness and function scales and HADS26 at baseline 
and after 12 weeks treatment. All endpoints were specified 
prospectively.
Pain algometry
Pain pressure thresholds (PPTs) were used to obtain objective 
measures of peripheral pain sensitization as we described previ-
ously.27 Briefly, a calibrated digital hand held algo meter (FDX 
100; Wagner Instruments, Greenwich, CT, USA) was used for 
all measurements. A standard operating procedure was used, 
which consisted of testing pain thresholds in all participants 
in both hands with n=30 regions for each participant, 780 
regions in total. Regions tested included dorsal aspects of all 
distal interphalangeal, proximal interphalangeal and metacar-
pophalangeal joints of each digit and thumb and the dorsum 
of each wrist. The 1 cm2 flat rubber algometer probe was held 
perpendicular to the dorsal aspect of the skin, and force was 
applied to provide a constant increase in pressure at a rate 
of 1 N/cm2/s. Therefore, the algometer scores are stated as 
Newton per centimeter squared in all reported results. The indi-
vidual was asked to say “stop” when the sensation of pressure 
became the first sensation of pain. The algometer was applied 
to each joint being examined three times in succession with 
an interval between applications. After all three readings were 
taken, the average from the last two readings was calculated as 
the PPT. The intervals between each algometer measurement 
were long enough to prohibit temporal summation.
Statistical analysis
Our sample size was based on IMMPACT guidelines25 and 
OARSI recommendations for RCTs in hand OA28 using 
NRS pain for the sample size calculation. For the NRS pain 
 outcome, we aimed to detect a mean difference of 2.0 (SD 
1.9) points between baseline and treatment after 12 weeks. 
With 16 participants in each group, 80% power with a 0.05 
significance level (two sided) is achieved. Recruitment 
required up to 22 participants per treatment group, allow-
ing a dropout rate of 25%, giving a total intervention study 
number of 65 participants to achieve desired statistical power.
Planned analyses included initial comparison to detect 
any significant differences between baseline and 13-week 
timepoints using primary endpoint NRS and AUSCAN 
pain difference between all three groups by ANOVA, with a 
multiple comparisons test, alpha =0.05. Following ANOVA, 
pairwise comparisons were performed for placebo vs prega-
balin and placebo vs duloxetine. The intent-to-treat analysis 
was performed using the last observation at week 13 and 
carried forward for all participants. We present the NRS 
pain and AUSCAN pain, stiffness, and function outcomes 
as mean and confidence interval for all analyses. These are 
presented after checking the distribution of the data, which 
followed a normal distribution and were not skewed for the 
parameters measured. We also show the per protocol analysis 
for all completers.
For the comparison of pain pressure algometry (PPT) 
in non-OA vs OA participants, Mann–Whitney U was used 
( Figure 1A). For correlation analyses between AUSCAN 
scores and PPT, an R2 correlation and P-value were calcu-
lated using GraphPad Prism (Figure 1B). In the bivariate 
comparisons of clinical outcome measures and PPT, SPSS 
was used to calculate an R2 correlation and P-value (Table 1).
We used IBM SPSS Statistics 21.0 for all analyses. Graphs 
were plotted using SPSS or GraphPad Prism  Version 7.
Results
Characteristics of patient population
Between April 2013 and April 2016, we recruited 65 partici-
pants (Figure 2). A total of 21 participants were randomized 
to duloxetine, a further 22 participants were randomized to 
pregabalin, and 22 participants were randomized to placebo, 
respectively. There were 20 age-matched healthy volunteer 
participants enrolled for the comparison of pain scores using 
algometry and brain MRI (MRI data from this study will be 
reported separately). All 65 participants who were random-
ized to treatment were included in the intention-to-treat (ITT) 
analysis. A total of 52 participants completed the trial proce-
dures after 13 weeks and were included in the per protocol 
analyses (Figure 3). Baseline characteristics show that the 
three treatment groups were well-matched for demographic 
data (Table 2). The mean disease duration was 3.5 years 
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(SD 4.2), which was measured from the time that the partici-
pant was first told that they had a diagnosis of hand OA. For 
prior analgesic use, there was slightly less acetaminophen use 
at baseline before enrollment in the duloxetine group than in 
the pregabalin and placebo groups, but for other NSAIDs and 
opiates, analgesic use was similar in all three groups.
Patient-reported outcomes
ITT analysis
Participants in all three groups receiving duloxetine, pregabalin, 
or placebo reported improvement in pain at the end of the trial. 
Comparison of the three groups by ANOVA showed a signifi-
cant difference at the end of treatment for NRS pain (P=0.035) 
and AUSCAN pain (P=0.0078) at the end of the trial. Following 
the primary analysis, pairwise comparisons were performed.
Pregabalin
Comparison of pregabalin vs placebo showed a significant 
improvement in the pregabalin group for primary outcomes 
of NRS pain (P=0.023), AUSCAN pain (P=0.008), and 
AUSCAN function (P=0.009) but not AUSCAN stiffness 
(P=0.22) scores (Table 3 and Figure 4).
Figure 1 Pain sensitization characteristics of study population.
Notes: (A) Data from the DUPRO clinical trial demonstrating reduced pain thresholds globally in the wrist and finger joints in hand OA participants compared to normal 
age- and sex-matched controls. (B) Graphs demonstrating correlation for PPT in Newton per centimeter squared at baseline with clinical measures for AUSCAN_P, 
AUSCAN_S, and AUSCAN_F in all groups.
Abbreviations: AUSCAN_P, Australian and Canadian Hand Osteoarthritis Index pain; AUSCAN_S, Australian and Canadian Hand Osteoarthritis Index stiffness; 
AUSCAN_F, Australian and Canadian Hand Osteoarthritis Index function; OA, osteoarthritis; PPT, pain pressure threshold; QST, quantitative sensory testing.
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Table 1 Bivariate correlation analysis of clinical scores in study
AUSCAN_P AUSCAN_S AUSCAN_F QST HADS_A HADS_D
NRS 0.606 0.268 0.471 -0.167 -0.010 0.158
0.000 0.034 0.000 0.203 0.938 0.216
AUSCAN_P 0.251 0.716 -0.234 0.171 0.328
0.047 0.000 0.072 0.179 0.009
AUSCAN_S 0.331 -0.429 0.230 0.213
0.008 0.001 0.070 0.093
AUSCAN_F -0.409 0.132 0.294
0.001 0.304 0.019
QST -0.285 -0.187
0.027 0.152
HADS_A 0.692
0.000
Abbreviations: AUSCAN_P, Australian and Canadian Hand Osteoarthritis Index pain; AUSCAN_S, Australian and Canadian Hand Osteoarthritis Index stiffness; 
AUSCAN_F, Australian and Canadian Hand Osteoarthritis Index function; HADS, Hospital Anxiety and Depression Scale; NRS, Numerical Rating Scale; QST, quantitative 
sensory testing.
Figure 2 CONSORT flow diagram for the DUloxetine or PRegabalin for Osteoarthritis pain (DUPRO) clinical trial.
628 patients were screened 345 did not respond after initial trial
information sent
169 were ineligible
37 declined to participate
12 did not meet all the inclusion
criteria65 were randomized
21 were allocated to duloxetine
Discontinued intervention n=5
1 developed bronchitis and
withdrew, 4 withdrew due to
side effects
16 completed trial 17 completed trial
13 subjects withdrew from study/lost to follow-up
20 control non-OA participants recruited
19 completed trial
Discontinued intervention n=5
1 withdrew due to a family
bereavement, 1 was noncompliant
with medication, 1 participant lost to
follow-up, 2 withdrew due to side effects
Discontinued intervention n=3
2 lost to follow-up
1 withdrew due to side effects
22 were allocated to pregabalin 22 were allocated to placebo
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Figure 3 Study flow diagram and outcome measures.
Abbreviations: AUSCAN, Australian and Canadian Hand Osteoarthritis Index; HADS, Hospital Anxiety and Depression Scale; NRS, Numerical Rating Scale; OA, 
osteoarthritis.
Participants with
hand OA and non-OA
controls
Interventions with 1:1:1 randomization
3 groups
Duloxetine
Pregabalin
Placebo
Non-OA controls did not receive medication
Week 1
Baseline visit
randomization
1 capsule at night
placebo or
30 mg duloxetine or
150 mg pregabalin
Dose escalation
2 capsules daily
placebo or
60 mg duloxetine or
300 mg pregabalin
Dose down-titration
1 capsule at night
placebo or
30 mg duloxetine or
150 mg pregabalin
Primary outcomes:
AUSCAN hand pain score
AUSCAN function/stiffness score
HADS, pain pressure thresholds
Brain neuroimaging
NRS for pain
Secondary outcomes:
End of study
collection of primary
and secondary
outcome data
Week 2 Week 11 Week 13
Table 2 Baseline characteristics of study patients (ITT analysis)
Characteristics Pregabalin (n=22) Duloxetine (n=21) Placebo (n=22)
Age (years), mean (SD) 64.0 (5.0) 62.3 (7.3) 62.4 (8.7)
Women 19 (86.4) 14(66.7) 19 (86.4)
White
Black
Asian
20 (90.9)
2 (9.1)
20 (95.2)
1 (4.8)
18 (81.8)
1 (4.6)
3 (13.6)
Body mass index, mean (SD) 27.1 (6.3) 28.4 (5.9) 27.0 (4.3)
NRS, mean (SD) 6.1 (1.2) 6.4 (1.5) 6.4 (1.4)
AUSCAN pain score, mean (SD) 317.0 (81.4) 296.0 (105.2) 320.3 (66.2)
HADS, mean (SD) 11.6 (7.4) 10.3 (6.1) 12.2 (6.2)
Most common analgesics before inclusion
Acetaminophen
Other NSAID oral/topical
Codeine-based analgesic
15
7
3
8
5
4
15
5
6
Note: Values are numbers (percentages) unless stated otherwise.
Abbreviations: AUSCAN, Australian and Canadian Hand Osteoarthritis Index; HADS, Hospital Anxiety and Depression Scale; ITT, intention-to-treat; NRS, Numerical 
Rating Scale; NSAID, nonsteroidal anti-inflammatory drug.
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Duloxetine
For NRS pain and AUSCAN pain, function, and stiffness 
outcomes in patients receiving duloxetine compared to pla-
cebo, none of these outcomes were significantly different to 
placebo (Table 3).
Use of rescue medication
Average use of acetaminophen as rescue medication was 
much lower in the pregabalin and duloxetine groups than in 
the placebo group (Table 3). The use of rescue medication in 
the placebo group was higher, amounting to 56 days.
Per protocol analysis
There was a reduction in reporting pain in all three groups at the 
end of the trial. A significant difference between the three groups 
at the end of treatment for NRS pain score (P=0.04) was found 
by ANOVA. Pairwise comparisons between duloxetine and 
placebo, pregabalin, and placebo were then performed (Table 4).
Pregabalin
For NRS pain, pregabalin was more effective than placebo 
(P<0.0001). Similarly, compared to placebo, there was a 
significant improvement in the pregabalin group for AUS-
CAN pain (P=0.013), AUSCAN function (P=0.02) but not 
AUSCAN stiffness (P=0.06).
Duloxetine
For the comparison between placebo and duloxetine treat-
ment, duloxetine was more effective as measured by NRS 
after 13 weeks (P=0.029). For AUSCAN pain, stiffness, and 
function outcomes in patients receiving duloxetine, these 
outcomes did not reach statistical significance.
Adverse events
Side effects were recorded prospectively throughout the study 
(Table 5). The placebo group showed fewer adverse events 
with a total of 22 recorded, with no difference in adverse 
Table 3 Primary and secondary outcomes in ITT population
Outcome at 13  weeks Pregabalin (N=22) Duloxetine (N=21) Placebo (N=22)
NRS
Baseline (95% CI)
13 weeks (95% CI)
Mean difference (95% CI)
P-value
6.1 (5.6 to 6.7)
3.4 (2.4 to 4.4)
–2.7 (–3.5 to –1.9)
0.023*
6.4 (5.7 to 7.1)
4.3 (2.6 to 5.9)
–2.3 (–3.8 to –0.9)
0.19
6.4 (5.7 to 6.9)
5.4 (4.1 to 6.8)
–0.9 (–0.2 to 0.2)
AUSCAN pain score
Baseline (95% CI)
13 weeks (95% CI)
Mean difference (95% CI)
P-value 
317.0 (280.8 to 353.1)
176.5 (123.9 to 229.1)
–132.1 (–181.1 to –82.9)
0.008*
296.0 (248.2 to 343.9)
248.1 (162.3 to 333.9)
–35.8 (–119.7 to 48.2)
0.59
320.3 (290.9 to 349.6)
273.5 (218.0 to 329.0)
–46.61 (–93.9 to 0.75)
AUSCAN stiffness
Baseline (95% CI)
13 weeks (95% CI)
Mean difference (95% CI)
P-value 
60.18 (51.7 to 68.7)
36.5 (23.0 to 49.9)
–18.7 (–33.1 to –4.3)
0.22
60.95 (46.98 to 74.9)
48.25 (29.87 to 66.6)
–13.5 (–26.5 to –0.6)
0.96
55.5 (45.2 to 65.8)
50.0 (36.0 to 64.0)
–5.67 (–16.8 to 5.5)
AUSCAN function
Baseline (95% CI)
13 weeks (95% CI)
Mean difference (95% CI)
P-value
576.2 (499.1 to 653.4)
362.2 (281.7 to 442.7)
–246.4 (–341.7 to –151.0)
0.009*
577.2 (478.0 to 676.4)
496.4 (342.4 to 650.5)
–101.8 (–248.4 to –44.7)
>0.05
582.3 (509.1 to 655.5)
508.7 (379.5 to 637.9)
–67.3 (–156.4 to –21.8)
Consumption of rescue medication  
(total number of days)
9 5 56
HADS
Anxiety
Baseline (95% CI)
13 weeks (95% CI)
Mean difference (95% CI)
P-value
Depression
Baseline (95% CI)
13 weeks (95% CI)
Mean difference (95% CI)
P-value
6.5 (4.6 to 8.4)
5.2 (2.9 to 7.5)
–0.82 (–2.1 to 0.5)
0.15
5.1 (3.6 to 6.7)
4.1 (2.6 to 5.6)
–1.1 (–2.1 to –0.02)
0.66
5.9 (4.3 to 7.6)
4.3 (2.2 to 6.3)
–1.3 (–3.1 to 0.5)
0.07
4.4 (2.9 to 5.8)
3.8 (1.9 to 5.7)
–0.3 (–1.9 to 1.2)
0.99
7.2 (5.4 to 9.0)
8.2 (6.4 to 9.9)
0.5 (–0.4 to 1.4)
4.9 (3.6 to 6.2)
5.1 (3.9 to 6.3)
0.05 (–1.3 to 1.4)
Notes: *Indicates significant at <0.05
Abbreviations: AUSCAN, Australian and Canadian Hand Osteoarthritis Index; HADS, Hospital Anxiety and Depression Scale; ITT, intention-to-treat; NRS, Numerical 
Rating Scale.
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events between the three groups (P=0.73). The highest 
reporting of adverse events was observed in the pregabalin 
and duloxetine groups: 55 adverse events were recorded 
with pregabalin, the most common of which were mental 
disturbance, headaches, sleepiness, dizziness, and dry mouth. 
In the duloxetine group, a total of 57 adverse events were 
recorded; there were a total of four withdrawals due to drug 
side effects and one participant withdrew due to the develop-
ment of bronchitis, as shown in the CONSORT flow diagram 
(Figures 3 and 5). For the pregabalin group, there were two 
withdrawals due to drug side effects, one withdrawal due to 
a family bereavement, one withdrawal due to noncompliance, 
and one withdrawal due to loss to follow-up.
Pain sensitization by PPT and relation to clinical 
scores
Using PPT testing as a measure for pain sensitization, 
compared to non-OA controls, the hand arthritis group had 
globally reduced pain thresholds (P<0.0001) across all finger 
joints at baseline, even at the metacarpophalangeal joints 
and wrists where there was little evidence of radiographic 
OA (Figure 1A). We investigated the correlation between 
the various clinical scores at baseline with age as a covari-
ate (Table 1). Measurements for the PPT modality of QST 
showed a significant correlation with AUSCAN stiffness 
(R2=0.188, P=0.0004) and function (R2=0.158, P=0.0014) 
for all patients at baseline (Figure 1B). There was a trend 
for lower PPT correlated with higher AUSCAN pain scores, 
although this trend did not reach statistical significance 
(P=0.06). NRS pain correlated strongly with AUSCAN pain 
and function (P<0.0001). PPT measures did not change sig-
nificantly in any of the three groups after 3 months treatment. 
We found that all participants with hand OA had lower PPT 
scores at baseline compared to healthy controls at inclusion 
and demonstrated a reduction of NRS at follow-up. HADS 
anxiety and depression scores were significantly correlated 
after Bonferroni correction. There were weaker correlations 
(significant without correction) between HADS depression 
and AUSCAN pain (P=0.009) and between AUSCAN func-
tion and stiffness scores (P=0.008).
Discussion
Principal findings
Our clinical study provides the first evidence in chronic pain-
ful hand OA that pregabalin and duloxetine are analgesics 
with potential for use in OA pain, with pregabalin providing 
the best treatment response and sustained effects beyond the 
reduction in dose. Second, we observed by QST that hand 
arthritis subjects have pain sensitization, which may include 
peripheral and central mechanisms. Third, the central but 
distinct actions of pregabalin and duloxetine could therefore 
be exerting an effect on central pain sensitization, which we 
Figure 4 (A,B) Plots for change in primary outcome measures in all treatment groups (ITT analysis).
Abbreviations: AUSCAN, Australian and Canadian Hand Osteoarthritis Index; ITT, intention-to-treat; NRS, Numerical Rating Scale.
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and others have demonstrated as a significant component 
of arthritic pain.14,15 Finally, we observed improvement for 
pregabalin in NRS for the ITT analysis, but not for dulox-
etine, with improvement in NRS for both active drugs only 
in the per protocol analysis. The results of our trial have 
strong clinical relevance, since many patients report lack of 
efficacy or side effects on NSAIDs and other patients have 
important safety concerns.
Study strengths and limitations
The lack of new analgesic targets for OA in this most 
common arthritic disease, coupled with recent data from 
animal models,18,19 prompted us to investigate the use of 
the gabapentinoid pregabalin and the SNRI duloxetine. 
Pregabalin is licensed for neuropathic pain29 and duloxetine 
for depression and diabetic neuropathic pain.30 Our proof-
of-concept trial demonstrated an improvement in pain for 
Table 4 Summary table for per protocol analysis
Outcome
at 13  weeks (imputed data on per  
protocol set)
Pregabalin Duloxetine Placebo
NRS
Baseline (95% CI)
13 weeks (95% CI)
Mean difference (95% CI)
P-value
6.1 (5.4 to 6.7)
3.4 (2.4 to 4.4)
–2.7 (–3.5 to –1.9)
<0.0001*
6.6 (5.7 to 7.4)
4.3 (2.6 to 5.9)
–2.3 (–3.8 to –0.9)
0.029*
6.3 (5.6 to 6.9)
5.4 (4.1 to 6.6)
–0.9 (–2.3 to 0.2)
AUSCAN pain score
Baseline (95% CI)
13 weeks (95% CI)
Mean difference (95% CI)
P-value 
308.5 (262.6 to 354.5)
176.5 (123.9 to 229.1)
–132.0 (–181.1 to –82.9)
0.013*
310.6 (254.3 to 367.0)
248.1 (162.3 to 333.9)
–62.5 (–141.6 to 16.6)
0.9
321.1 (288.7 to 353.4)
273.5 (218.0 to 329.0)
–47.1 (–93.8 to 11.7)
AUSCAN stiffness
Baseline (95% CI)
13 weeks (95% CI)
Mean difference (95% CI)
P-value 
59.9 (51.8 to 67.9)
36.5 (23.0 to 49.9)
–23.4 (–35.7 to –11.1)
0.06
61.8 (45.8 to 77.8)
48.3 (29.9 to 66.6)
–13.5 (–26.5 to –0.6)
0.46
56.1 (44.5 to 67.7)
50.0 (36.0 to 64.0)
5.7 (–16.8 to 5.5)
AUSCAN function
Baseline (95% CI)
13 weeks (95% CI)
Mean difference (95% CI)
P-value
608.5 (541.3 to 675.7)
362.2 (281.7 to 442.7)
–246.3 (–341.7 to –151.0)
0.02*
598.3 (481.2 to715.3)
496.4 (342.4 to 650.5)
–101.9 (–248.4 to –44.8)
0.93
580.0 (494.6 to 665.4)
508.7 (379.5 to 637.9)
–69.7 (–158.3 to –18.9)
Consumption of rescue medication 
(total number of days)
9 5 56
HADS
Anxiety
Baseline (95% CI)
13 weeks (95% CI)
Mean difference (95% CI)
P-value
Depression
Baseline (95% CI)
13 weeks (95% CI)
Mean difference (95% CI)
P-value
6.1 (3.8 to 8.3)
5.2 (2.9 to 7.5)
–0.82 (–2.1 to 0.5)
0.52
5.1 (3.3 to 6.9)
4.1 (2.6 to 5.6)
–1.1 (–2.1 to –0.02)
0.41
5.6 (3.6 to 7.5)
4.3 (2.2 to 6.3)
–1.3 (–3.1 to 0.5)
0.21
4.1 (2.3 to 5.9)
3.8 (1.9 to 5.7)
–0.3 (–1.8 to 1.2)
0.54
7.6 (5.8 to 9.5)
8.2 (6.4 to 9.9)
0.5 (–0.4 to 1.4)
0.71
5.4 (4.0 to 6.7)
5.1 (3.9 to 6.3)
0.05 (–1.3 to 1.4)
0.93
Notes: *Indicates significant at <0.05
Abbreviations: AUSCAN, Australian and Canadian Hand Osteoarthritis Index; HADS, Hospital Anxiety and Depression Scale; NRS, Numerical Rating Scale.
pregabalin and also for duloxetine after 13 weeks treatment. 
We enrolled subjects who had an NRS pain rating of at 
least 5 to ensure that clinically meaningful improvements 
in pain could be detected. There were some differences in 
our ITT and per protocol analysis: in ITT, pregabalin, but 
not duloxetine, showed a significant improvement in pain 
compared to placebo; and in the per protocol analysis, 
both agents showed an improvement in pain. Although 
we observed an improvement in pain reporting for both 
centrally acting agents, pregabalin was more effective after 
13 weeks. In our secondary endpoint analyses, we did not 
see any significant improvement in depression or anxiety 
scores in any treatment group.
Since this was a proof-of-concept analgesic endpoint 
study, we did not collect structural outcome data including 
joint damage progression changes by plain radiograph and 
synovitis by ultrasound, as described in other studies,31–34,37 
 
Jo
ur
na
l o
f P
ai
n 
Re
se
ar
ch
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
4.
82
.5
0.
2 
on
 1
0-
No
v-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Pain Research  2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2446
Sofat et al
which could be addressed in future work. We also recognize 
that our study has been conducted in hand arthritis pain, 
whereas several large previous datasets have focused on 
knee OA,35–37 and there may be some differences in pain 
characteristics including loading effects due to structural 
joint differences between the hand and knee.
Main results in context of other 
literature
In knee OA, Chappell et al17 showed that duloxetine was 
effective for pain, Ohtori et al20 found that pregabalin with 
meloxicam was more effective than pregabalin alone, and our 
data show that both agents have efficacy in chronic hand OA 
pain with pregabalin showing superiority over duloxetine.
Recent concepts in novel therapeutic agents for OA have 
included potential therapeutics for structural changes in the 
joint including synovitis31 and bone marrow lesions (BML).32 
Table 5 Side effect profile in all three treatment groups from 
ITT analysis
System Pregabalin  
(N=22)
Duloxetine  
(N=21)
Placebo  
(N=22)
Cardiovascular 3 2 1
Digestive 7 18 5
ENT 2
Endocrine/metabolic 1
Genitourinary 1
Hematological
Mental 9 9 9
Nervous system
Dry mouth
Headaches
Dizziness
Sleepiness
Loss of balance
6
3
7
5
7
6
8
3
3
4
Ophthalmological 4 2 1
Respiratory 2 3
Skin 1 2
Total 55 57 22
Abbreviations: ENT, ear, nose and throat; ITT, intention-to-treat.
Item 
number
Checklist item Page number*
Title and abstract
1a Identification as a randomized trial in the title Yes Title
1b Structured summary of trial design, methods, results, and conclusions  Yes Abstract
Introduction
Background and 
objectives
2a Scientific background and explanation of rationale  Yes Introduction
Paragraphs 1–3
2b Specific objectives or hypotheses  Yes Introduction
Paragraph 4
Methods
Trial design 3a Description of trial design (such as parallel and factorial) including a 
location ratio  Yes
Methods, trial design, and 
participants section
3b Important changes to methods after trial commencement  
(such as eligibility criteria), with reasons  Yes
Methods and statistical analysis 
section
Participants 4a Eligibility criteria for participants  Yes Methods, study design, and 
participants section
4b Settings and locations where the data were collected  Yes Methods, study design, and 
participants section
Interventions 5 The interventions for each group with sufficient details to allow 
replication, including how and when they were actually administered  Yes
Methods and study design
Outcomes 6a Completely defined pre-specified primary and secondary outcome  
measures, including how and when they were assessed  Yes
Methods and outcome section
6b Any changes to trial outcomes after the trial commenced, with reasons Not applicable
Sample size 7a How sample size was determined  Yes Methods and statistical analysis 
section
7b When applicable, explanation of any interim analyses and stopping guidelines Not applicable
Randomization
  Sequence 
generation
8a Method used to generate the random allocation sequence  Yes Methods, randomization, and 
masking section
8b Type of randomization; details of any restriction (such as blocking  
and block size)  Yes
Methods, randomization, and 
masking section
Figure 5 (Continued)
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Item 
number
Checklist item Page number*
  Allocation 
concealment 
mechanism
9 Mechanism used to implement the random allocation sequence 
(such as sequentially numbered containers), describing any steps 
taken to conceal the sequence until interventions were assigned  Yes 
Methods, randomization, and 
masking section
 Implementation 10 Who generated the random allocation sequence, who enrolled 
participants, and who assigned participants to interventions  Yes
Methods, randomization, and 
masking section
Blinding 11a If done, who was blinded after assignment to interventions 
(for example, participants, care providers, those assessing outcomes)  
and how  Yes
Methods, randomization, and 
masking section
11b If relevant, description of the similarity of interventions Not applicable
Statistical methods 12a Statistical methods used to compare groups for primary and 
secondary outcomes  Yes
Methods and statistical analysis 
section
12b Methods for additional analyses, such as subgroup analyses and 
adjusted analyses  Yes
Methods and statistical analysis 
section
Results
Participant 
flow (a diagram 
is strongly 
recommended)
13a For each group, the numbers of participants who were randomly  
assigned, received intended treatment, and were analyzed for the  
primary outcome  Yes
Figure 2 CONSORT diagram
13b For each group, losses and exclusions after randomization,  
together with reasons  Yes
Figure 2 CONSORT diagram
Recruitment 14a Dates defining the periods of recruitment and follow-up  Yes Methods, study design, and 
participants section
14b Why the trial ended or was stopped Not applicable
Baseline data 15 A table showing baseline demographic and clinical characteristics 
for each group  Yes
Table 2 from paper
Numbers analyzed 16 For each group, number of participants (denominator) included 
in each analysis and whether the analysis was by original  
assigned groups  Yes
Results, participant section, and 
CONSORT diagram, Figure 2
Outcomes and 
estimation
17a For each primary and secondary outcome, results for each group, 
and the estimated effect size and its precision (such as 95% 
confidence interval)  Yes
Table 3 from paper
17b For binary outcomes, presentation of both absolute and relative  
effect sizes is recommended
Not a binary outcome
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses  
and adjusted analyses, distinguishing prespecified from exploratory  Yes
Results and Figure 1
Harms 19 All important harms or unintended effects in each group  Yes Results, adverse events section, 
and Table 5
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, 
and, if relevant, multiplicity of analyses  Yes
Discussion, study strengths, and 
limitations
Generalizability 21 Generalizability (external validity, applicability) of the trial findings  Yes Discussion, study strengths, and 
limitations, implications for practice 
and future research
Interpretation 22 Interpretation consistent with results, balancing benefits and 
harms, and considering other relevant evidence Yes
Discussion, section main results in 
context of other literature
Other information
Registration 23 Registration number and name of trial registry  Yes Abstract
Protocol 24 Where the full trial protocol can be accessed, if available  Yes Clinicaltrials.gov
Funding 25 Sources of funding and other support (such as supply of drugs), 
role of funders  Yes
Included in declaration submission
Figure 5 CONSORT 2010 checklist of information for the DUloxetine or PRegabalin for Osteoarthritis pain (DUPRO) randomized controlled trial.
Note: *Page numbers optional depending on journal requirements. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting 
randomised trials in journal and conference abstracts. Lancet. 2008;371:281–283.38
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However, such studies have not been without difficulty since 
recent trials targeting the inflammatory component of OA 
have not shown improved outcomes33 and the use of bisphos-
phonates potentially for reducing BML-related pain need 
to define significant clinical and structural endpoints.34 It is 
possible that patients demonstrating a largely “inflammatory” 
phenotype are likely to benefit from agents such as NSAIDs, 
and when there are features of sensitization with ongoing 
pain, patients may require additional treatment such as cen-
trally acting agents including pregabalin and duloxetine. In 
the clinic, patients may also require additional treatments 
if NSAIDs are linked to side effects, lack of efficacy, and 
ongoing pain.
There is recognition that pain sensitization occurs in 
people with OA.11–15,35–37 The main indication from our data 
of peripheral sensitization in hand OA is that the control 
subjects had significantly higher PPTs than the hand OA 
group. We noted that PPTs did not change significantly after 
treatment, suggesting that pathways which led to sensitization 
in hand arthritis may continue to exist in the patients even 
after drug treatment.
Implications for practice and future 
research
Pregabalin and duloxetine had efficacy in hand OA pain in 
our clinical study, with pregabalin showing greater effect 
than duloxetine for validated pain endpoints. In our study, 
one or more of the following analgesics had been used by 
more than half of the participants prior to enrollment in the 
study: acetaminophen, NSAID, or codeine-based analgesics. 
When such analgesics had not previously been effective, our 
trial showed that pregabalin, and to a less significant degree 
duloxetine, may provide a realistic alternative to pain manage-
ment in OA. In future, clinical trials that examine the efficacy 
of centrally acting analgesics over a longer treatment period 
of >12 weeks in chronic arthritic pain should be conducted. 
Further studies measuring peripheral and central sensitiza-
tion will be crucial to understand how pain, loss of function, 
comorbid conditions, and medication use contribute to the 
development of arthritic pain.
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